AU2013369288B2 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same - Google Patents

Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same Download PDF

Info

Publication number
AU2013369288B2
AU2013369288B2 AU2013369288A AU2013369288A AU2013369288B2 AU 2013369288 B2 AU2013369288 B2 AU 2013369288B2 AU 2013369288 A AU2013369288 A AU 2013369288A AU 2013369288 A AU2013369288 A AU 2013369288A AU 2013369288 B2 AU2013369288 B2 AU 2013369288B2
Authority
AU
Australia
Prior art keywords
propyl
disease
pct
sulphate salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013369288A
Other languages
English (en)
Other versions
AU2013369288A8 (en
AU2013369288A1 (en
Inventor
Mathieu BARRIER
Luc Buee
Stephane Burlet
Cecilia Estrella
Patricia Melnyk
Nicolas Sergeant
Philippe Verwaerde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALZPROTECT
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Original Assignee
ALZPROTECT
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALZPROTECT, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Lille filed Critical ALZPROTECT
Publication of AU2013369288A1 publication Critical patent/AU2013369288A1/en
Publication of AU2013369288A8 publication Critical patent/AU2013369288A8/en
Application granted granted Critical
Publication of AU2013369288B2 publication Critical patent/AU2013369288B2/en
Priority to AU2018202218A priority Critical patent/AU2018202218B2/en
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ALZPROTECT, Université de Lille reassignment INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) Request for Assignment Assignors: ALZPROTECT, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LILLE 2 DROIT ET SANTE
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013369288A 2012-12-27 2013-12-27 Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same Active AU2013369288B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018202218A AU2018202218B2 (en) 2012-12-27 2018-03-28 Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl) -1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP12306690.4 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018202218A Division AU2018202218B2 (en) 2012-12-27 2018-03-28 Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl) -1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (3)

Publication Number Publication Date
AU2013369288A1 AU2013369288A1 (en) 2015-07-02
AU2013369288A8 AU2013369288A8 (en) 2015-07-16
AU2013369288B2 true AU2013369288B2 (en) 2018-02-22

Family

ID=47501005

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013369288A Active AU2013369288B2 (en) 2012-12-27 2013-12-27 Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
AU2018202218A Active AU2018202218B2 (en) 2012-12-27 2018-03-28 Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl) -1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018202218A Active AU2018202218B2 (en) 2012-12-27 2018-03-28 Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl) -1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Country Status (23)

Country Link
US (3) US9562018B2 (enExample)
EP (1) EP2938597B1 (enExample)
JP (1) JP6384923B2 (enExample)
KR (1) KR102115060B1 (enExample)
CN (1) CN105008333B (enExample)
AU (2) AU2013369288B2 (enExample)
BR (1) BR112015015474B1 (enExample)
CA (1) CA2895285C (enExample)
DK (1) DK2938597T3 (enExample)
ES (1) ES2605494T3 (enExample)
HR (1) HRP20161612T2 (enExample)
HU (1) HUE030930T2 (enExample)
IL (1) IL239450B (enExample)
LT (1) LT2938597T (enExample)
MX (1) MX363367B (enExample)
NZ (1) NZ708959A (enExample)
PL (1) PL2938597T3 (enExample)
PT (1) PT2938597T (enExample)
RS (1) RS55511B1 (enExample)
RU (1) RU2655454C2 (enExample)
SI (1) SI2938597T1 (enExample)
WO (1) WO2014102339A1 (enExample)
ZA (1) ZA201504521B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55511B1 (sr) * 2012-12-27 2017-05-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba
WO2016146655A1 (en) 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途
DK4225306T3 (da) * 2020-10-07 2025-03-24 Alzprotect Anvendelse af n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-aminsulfatsalte og solvater heraf til behandling af motorneuronsygdomme og neuromuskulære forbindelseslidelser
MX2024007691A (es) 2021-12-20 2024-07-01 Alzprotect Uso de sales de succinato de n-(3-(4-(3-(diisobutilamino)propil)pi perazin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos del mismo para el tratamiento de enfermedades de las neuronas motoras y trastornos de la union neuromuscular.
US20250205226A1 (en) 2022-03-25 2025-06-26 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051489A1 (en) * 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
WO1998056423A1 (fr) * 1997-06-12 1998-12-17 Transgene S.A. Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
HK1038749A1 (zh) 1998-09-30 2002-03-28 纽罗根公司 2-哌嗪烷基氨苯并吡咯衍生物:多巴胺受体亚型特异配体
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
EP1581517B1 (en) * 2002-12-23 2007-02-21 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
RS55511B1 (sr) * 2012-12-27 2017-05-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006051489A1 (en) * 2004-11-10 2006-05-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
US20170151235A1 (en) 2017-06-01
US20190381036A1 (en) 2019-12-19
AU2013369288A8 (en) 2015-07-16
HUE030930T2 (hu) 2017-06-28
DK2938597T3 (en) 2017-01-09
US9562018B2 (en) 2017-02-07
ZA201504521B (en) 2016-11-30
NZ708959A (en) 2019-11-29
SI2938597T1 (sl) 2017-03-31
HRP20161612T2 (hr) 2017-02-24
MX2015008502A (es) 2015-12-16
IL239450A0 (en) 2015-07-30
BR112015015474B1 (pt) 2022-04-19
AU2018202218A1 (en) 2018-04-26
RU2655454C2 (ru) 2018-05-29
BR112015015474A2 (enExample) 2017-08-15
ES2605494T3 (es) 2017-03-14
US20160108003A1 (en) 2016-04-21
US10537569B2 (en) 2020-01-21
CN105008333A (zh) 2015-10-28
HRP20161612T1 (hr) 2017-01-27
US10772884B2 (en) 2020-09-15
KR20150105313A (ko) 2015-09-16
MX363367B (es) 2019-03-20
CA2895285C (en) 2021-03-30
AU2018202218B2 (en) 2019-02-21
EP2938597B1 (en) 2016-10-26
JP6384923B2 (ja) 2018-09-05
LT2938597T (lt) 2017-01-25
RU2015130671A (ru) 2017-01-30
EP2938597A1 (en) 2015-11-04
IL239450B (en) 2018-06-28
HK1215582A1 (en) 2016-09-02
AU2013369288A1 (en) 2015-07-02
CA2895285A1 (en) 2014-07-03
PL2938597T3 (pl) 2017-03-31
CN105008333B (zh) 2018-02-09
WO2014102339A1 (en) 2014-07-03
RS55511B1 (sr) 2017-05-31
PT2938597T (pt) 2016-12-09
KR102115060B1 (ko) 2020-05-25
JP2016503813A (ja) 2016-02-08

Similar Documents

Publication Publication Date Title
AU2018202218B2 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl) -1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
ES2915833T3 (es) Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
ES2652187T3 (es) Fenilacetato de l-ornitina y métodos para elaborar el mismo
US10472353B2 (en) Salt and crystal forms of PLK-4 inhibitor
EP4353723A1 (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
WO2013134371A1 (en) Methods and compounds to be used in the treatment of neurodegenerative diseases
ES2924432T3 (es) Polimorfos cristalinos de un agonista del receptor de la acetilcolina muscarínica
AU2021353998B2 (en) Succinate salts of N-(3-(4-(3-(Diisobutylamino)Propyl)Piperazin-1-YL)Propyl)-1H-Benzo[D]Imidazol-2-Amine, Preparation Thereof And Use Of The Same
HK1215582B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
HK40111001A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
HK1225651B (zh) 异吲哚啉组合物和治疗神经变性疾病的方法

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 25 , PAGE(S) 3709 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME UNIVERSITE LILLE 2 DROIT ET SANTE; ALZPROTECT, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), APPLICATION NO. 2013369288, UNDER INID (71) CORRECT THE APPLICANT NAME TO UNIVERSITE DE LILLE 2 DROIT ET SANTE, UNDER INID (54) CORRECT THE TITLE TO READ SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1HBENZO(D)IMIDAZOL-2-AMINE, PREPARATION THEREOF AND USE OF THE SAME

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: UNIVERSITE DE LILLE

Free format text: FORMER OWNER(S): UNIVERSITE DE LILLE 2 DROIT ET SANTE; ALZPROTECT; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Free format text: FORMER OWNER(S): UNIVERSITE DE LILLE 2 DROIT ET SANTE; ALZPROTECT; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

Owner name: ALZPROTECT

Free format text: FORMER OWNER(S): UNIVERSITE DE LILLE 2 DROIT ET SANTE; ALZPROTECT; INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)